Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
Edd SN, Castañeda J, Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Ré R, Cellot J, de Portu S, Vorrink L, Shin J, van den Heuvel T, Cohen O; ADAPT study Group. Edd SN, et al. Among authors: de portu s. Diabetes Obes Metab. 2023 Nov;25(11):3212-3222. doi: 10.1111/dom.15217. Epub 2023 Aug 8. Diabetes Obes Metab. 2023. PMID: 37551542 Clinical Trial.
Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring.
van den Heuvel T, Kolassa R, Keuthage W, Kroeger J, Ré R, de Portu S, Vorrink L, Shin J, Castañeda J, Vigersky R, Cohen O. van den Heuvel T, et al. Among authors: de portu s. J Diabetes Sci Technol. 2023 Mar 22:19322968231161320. doi: 10.1177/19322968231161320. Online ahead of print. J Diabetes Sci Technol. 2023. PMID: 36949671 Free article.
A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes.
Jendle J, Buompensiere MI, Ozdemir Saltik AZ, de Portu S, Smith-Palmer J, Pollock RF, Cohen O. Jendle J, et al. Among authors: de portu s. Diabetes Technol Ther. 2023 Dec;25(12):864-876. doi: 10.1089/dia.2023.0297. Diabetes Technol Ther. 2023. PMID: 37801658
Response to: Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands.
Serné EH, Roze S, Buompensiere MI, Valentine WJ, de Portu S, de Valk HW. Serné EH, et al. Among authors: de portu s. Adv Ther. 2023 May;40(5):2545-2548. doi: 10.1007/s12325-023-02431-2. Epub 2023 Mar 9. Adv Ther. 2023. PMID: 36892809 No abstract available.
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.
Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Ré R, de Portu S, Vorrink L, Shin J, Habteab A, Castañeda J, da Silva J, Cohen O; ADAPT study Group. Choudhary P, et al. Among authors: de portu s. Lancet Diabetes Endocrinol. 2022 Oct;10(10):720-731. doi: 10.1016/S2213-8587(22)00212-1. Epub 2022 Sep 1. Lancet Diabetes Endocrinol. 2022. PMID: 36058207 Clinical Trial.
A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden.
Jendle J, Buompensiere MI, Holm AL, de Portu S, Malkin SJP, Cohen O. Jendle J, et al. Among authors: de portu s. Diabetes Ther. 2022 May;13(5):1125-1129. doi: 10.1007/s13300-022-01252-w. Epub 2022 Apr 11. Diabetes Ther. 2022. PMID: 35403952 Free PMC article. No abstract available.
58 results